Abstract
Introduction: The diagnosis of pancreatic adenocarcinoma remains a devastating life event for most patients and their families. Many patients with this relatively common malignancy present at a stage of disease not amenable to cancer-directed resectional therapy, and are treated via nonoperative palliative measures, with median survival of 4-8 months post- diagnosis. Conclusion: A minority of patients present with disease limited to the pancreas and periampullary region and are candidates for resectional therapy. The prognosis for these patients is determined by several factors: clinicopathologic staging, tumor biology and molecular genetics, perioperative factors and the use of postoperative adjuvant therapy.
Original language | English (US) |
---|---|
Pages (from-to) | 129-133 |
Number of pages | 5 |
Journal | Langenbeck's Archives of Surgery |
Volume | 383 |
Issue number | 2 |
DOIs | |
State | Published - Apr 1998 |
Keywords
- Adjuvant chemoradiation therapy
- Pancreatic adenocarcinoma
- Tumor DNA content
- p53 tumor suppressor gene
ASJC Scopus subject areas
- Surgery